Analyzing InflaRx (NASDAQ:IFRX) & Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX) and InflaRx (NASDAQ:IFRX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Institutional and Insider Ownership

42.4% of InflaRx shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 16.3% of InflaRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Celldex Therapeutics and InflaRx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1	1	11	1	2.86
InflaRx	1	2	5	1	2.67

Celldex Therapeutics presently has a consensus price target of $61.92, indicating a potential upside of 98.98%. InflaRx has a consensus price target of $7.43, indicating a potential upside of 279.01%. Given InflaRx’s higher probable upside, analysts clearly believe InflaRx is more favorable than Celldex Therapeutics.

Volatility & Risk

Celldex Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500.

Earnings & Valuation

This table compares Celldex Therapeutics and InflaRx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54 million	1,586.92	-$258.76 million	($4.35)	-7.15
InflaRx	$30,000.00	9,628.17	-$51.63 million	($0.58)	-3.38

InflaRx has lower revenue, but higher earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Celldex Therapeutics and InflaRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
InflaRx	N/A	-53.56%	-43.02%

Summary

InflaRx beats Celldex Therapeutics on 9 of the 13 factors compared between the two stocks.

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.